Table 5.

Number (%) of patients with each condition poststudy

N (%) of patients
DFMO (N = 108)Placebo (N = 108)All (N = 209)P valuea
Hematologic malignancy4 (3.7)2 (2.0)6 (2.9)0.684
Prostate cancer5 (4.6)2 (2.0)7 (3.3)0.447
Noninvasive neoplasm23 (21.3)28 (27.7)51 (24.4)0.334
Cardiacb23 (21.3)22 (21.8)45 (21.5)1.000
Vascular disease22 (20.4)20 (19.8)42 (20.1)1.000
Diabetes mellitus type II8 (7.4)5 (5.0)13 (6.2)0.572
Neurologic disorders22 (20.4)17 (16.8)39 (18.7)0.595
Colonic polyps16 (14.8)11 (10.9)27 (12.9)0.418
Renal diseasec4 (3.7)2 (2.0)6 (2.9)0.684
Hepatic disordersd9 (8.3)3 (3.0)12 (5.7)0.137
Eye disorders7 (6.5)7 (6.9)14 (6.7)1.000
Death10 (9.3)6 (5.9)16 (7.7)0.441
  • aFisher exact test.

  • bChronic heart failure, valve disorders, coronary artery disease, abnormal ECG, endocarditis, abnormal heart rate, and cardiomegaly.

  • cChronic renal failure, abnormal creatinine, kidney cyst, and calculus.

  • dHepatitis, cholecystitis, hepatic cyst, abnormal liver function tests, ascites, microalbumin, and common bile duct obstruction.